Skip to main content

Table 2 Patient characteristics at NA discontinuation and outcomes in relation to the detectability of pgRNA at EOT

From: Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B

  Total
N = 74
pgRNA positive
N = 7
pgRNA negative
N = 67
p value
Patient characteristics at NA discontinuation
Age, years 60 (27–83) 64 (43–73) 60 (27–83) 0.561
Sex, females/males 19/55 2/5 17/50 0.855
NA genetic barrier, high/low 14/60 7/0 53/14 0.179
Duration of NA treatment, months 75 (36–220) 94 (36–167) 74 (36–220) 0.183
ALT, IU/L 21 (10–40) 23 (12–40) 21 (10–40) 0.432
HBsAg, log10 IU/mL 2.48 (ND–4.59) 2.73 (2.03–3.77) 2.3 (ND–4.59) 0.297
Outcomes after NA discontinuation
Virological relapse, n (%) 42 (57) 7 (100%) 35 (52%) 0.016
Clinical relapse, n (%) 21 (28) 5 (71%) 17 (25%) 0.011
Retreatment, n (%) 14 (19) 5 (71%) 9 (13%)  < 0.01
HBsAg loss, n (%) 33 (45) 0 33 (49%) 0.013
  1. Quantitative variables are presented as median (min–max) values, in bold statistically significant values (p < 0.05) are shown
  2. NA, nucleos(t)ide analogue; ND, not detectable